Disease Progression
A 6-stage journey from the gut to the cortex - Braak's hypothesis and the decades-long hidden disease.
Heiko Braak's Insight
In 2003, German neuroanatomist Heiko Braak published a landmark study examining the brains of people who had died with and without Parkinson's. By carefully mapping where Lewy body pathology accumulated, he discovered something remarkable: the disease does not start in the movement centers. Instead, it begins in the lowest, most ancient parts of the nervous system and slowly climbs toward the cortex over years to decades.
Braak proposed a six-stage classification, known as Braak staging, that maps this relentless upward march. Today, roughly 70–80% of PD cases show a progression consistent with this framework.
The stages explain a puzzle that had long confused clinicians: why do patients develop constipation, depression, and sleep disorders years before their tremor begins? The answer is that the disease is methodically working its way upward through the brain - the gut and brainstem are damaged first, the substantia nigra comes later.
What this actually means
A scientist named Heiko Braak discovered that Parkinson's does not start where tremors come from. It begins deep in the body -- in areas connected to the gut and nose -- and slowly climbs upward through the brain over many years.
Picture this: Imagine a wildfire that starts in the brush at the base of a mountain and slowly burns uphill, one ridge at a time. By the time the fire reaches the summit (the movement centres), the lower slopes have been burning for years.
Why it matters: This explains why gut problems, loss of smell, and sleep trouble appear years before tremor. The disease was already spreading -- doctors just were not looking in the right place yet.
Heiko Braak's Insight
In 2003, German neuroanatomist Heiko Braak published a landmark study examining the brains of people who had died with and without Parkinson's. By carefully mapping where Lewy body pathology accumulated, he discovered something remarkable: the disease does not start in the movement centers. Instead, it begins in the lowest, most ancient parts of the nervous system and slowly climbs toward the cortex over years to decades.
Braak proposed a six-stage classification, known as Braak staging, that maps this relentless upward march. Today, roughly 70–80% of PD cases show a progression consistent with this framework.
The stages explain a puzzle that had long confused clinicians: why do patients develop constipation, depression, and sleep disorders years before their tremor begins? The answer is that the disease is methodically working its way upward through the brain - the gut and brainstem are damaged first, the substantia nigra comes later.
Caudal-to-Rostral Spread - From Tail to Head
Caudal means "toward the tail" and rostralmeans "toward the nose." In humans, the brainstem sits at the caudal end of the brain (connecting to the spinal cord), while the cortex is the rostral top.
Braak staging traces a path from caudal to rostral: gut → vagus nerve → brainstem → midbrain → cortex. Alpha-synuclein pathology first appears at Stages 1 and 2 in the dorsal motor nucleus of the vagus (a brainstem structure connected directly to the gut) and the olfactory bulb (connected to the nose).
This staging explains why anosmia (loss of smell) is present in over 90% of PD patients, and why constipation - driven by enteric nervous system damage - affects 70–80% of patients, often appearing a decade or more before motor symptoms.
Approximate progression path
What this actually means
The disease travels upward through the brain like climbing a ladder -- starting at the bottom (gut connections and smell centre) and working its way up to the movement areas and eventually the thinking centres at the top.
Picture this: Think of a vine creeping up a trellis. It starts at the soil (the gut), wraps around the lowest rung (brainstem), and steadily climbs toward the top (cortex). Each rung it reaches brings new symptoms.
Why it matters: This bottom-to-top pattern is why over 90% of patients lose their sense of smell and 70-80% develop constipation years before any tremor appears. Those early signs are the vine reaching its first rungs.
Caudal-to-Rostral Spread - From Tail to Head
Caudal means "toward the tail" and rostralmeans "toward the nose." In humans, the brainstem sits at the caudal end of the brain (connecting to the spinal cord), while the cortex is the rostral top.
Braak staging traces a path from caudal to rostral: gut → vagus nerve → brainstem → midbrain → cortex. Alpha-synuclein pathology first appears at Stages 1 and 2 in the dorsal motor nucleus of the vagus (a brainstem structure connected directly to the gut) and the olfactory bulb (connected to the nose).
This staging explains why anosmia (loss of smell) is present in over 90% of PD patients, and why constipation - driven by enteric nervous system damage - affects 70–80% of patients, often appearing a decade or more before motor symptoms.
Approximate progression path
Compensatory Mechanisms - Why Symptoms Are Delayed
One of the most striking features of Parkinson's is how long the brain conceals the damage. Motor symptoms only emerge after 50–70% of substantia nigra neurons are lost and striatal dopamine has fallen by 70–80%. The brain achieves this through several compensatory strategies:
Increased firing rate
Surviving SNc neurons fire faster to compensate for the reduced cell count, temporarily maintaining adequate dopamine release.
Axonal sprouting
Remaining dopamine axons grow new terminals to cover the territory abandoned by dying cells - each SNc neuron already maintains an astonishing 1–2.4 million synapses.
Receptor upregulation
Dopamine receptors in the striatum become more sensitive, amplifying the signal from diminishing dopamine levels.
Network re-routing
Other brain regions partially take over functions previously dominated by the dopamine system.
These mechanisms are impressive but finite. Once 50–70% of neurons are lost, the remaining cells simply cannot keep up. The compensation fails - and symptoms appear suddenly from the patient's perspective, even though the underlying process has been ongoing for a decade or more.
What this actually means
The brain hides the damage for years. Surviving cells work overtime -- firing faster, growing new connections, and turning up the volume on their receivers. Symptoms only appear after more than half the cells are already gone.
Picture this: Imagine a team of 10 workers. As colleagues leave one by one, the remaining workers pick up extra shifts. Everything seems fine until only 3 are left -- then suddenly the workload collapses and nothing gets done. The decline looked sudden, but it had been building for years.
Why it matters: By the time someone is diagnosed with Parkinson's tremor, they have already lost the majority of these critical neurons. This is why researchers are so focused on detecting the disease during the long hidden phase, before the compensation runs out.
Common misconception: The sudden appearance of tremor does not mean the disease just started. The brain was compensating for years of damage before finally running out of capacity.
Compensatory Mechanisms - Why Symptoms Are Delayed
One of the most striking features of Parkinson's is how long the brain conceals the damage. Motor symptoms only emerge after 50–70% of substantia nigra neurons are lost and striatal dopamine has fallen by 70–80%. The brain achieves this through several compensatory strategies:
Increased firing rate
Surviving SNc neurons fire faster to compensate for the reduced cell count, temporarily maintaining adequate dopamine release.
Axonal sprouting
Remaining dopamine axons grow new terminals to cover the territory abandoned by dying cells - each SNc neuron already maintains an astonishing 1–2.4 million synapses.
Receptor upregulation
Dopamine receptors in the striatum become more sensitive, amplifying the signal from diminishing dopamine levels.
Network re-routing
Other brain regions partially take over functions previously dominated by the dopamine system.
These mechanisms are impressive but finite. Once 50–70% of neurons are lost, the remaining cells simply cannot keep up. The compensation fails - and symptoms appear suddenly from the patient's perspective, even though the underlying process has been ongoing for a decade or more.
The Six Stages - Interactive Timeline
Each stage corresponds to a different region being engulfed by alpha-synuclein pathology. Notice how symptoms at Stages 1–2 are entirely non-motor - they belong to the "hidden disease" that precedes any clinical diagnosis.
Stage 1: The Silent Beginning
Alpha-synuclein pathology appears in the brainstem's lowest levels and the olfactory system. The gut-brain connection via the vagus nerve may be the entry point.
Stage 2: Sleep and Mood
Pathology ascends to the lower pons, affecting noradrenergic and serotonergic centers. Sleep architecture begins to deteriorate.
Stage 3: The Tipping Point
The disease reaches the midbrain. Dopaminergic neurons begin dying in earnest, but compensatory mechanisms mask the damage. The countdown to clinical diagnosis begins.
Stage 4: Diagnosis
Compensation fails. Motor symptoms emerge as dopamine depletion crosses the critical threshold. This is when most patients receive their diagnosis.
Stage 5: Cognitive Decline
Lewy pathology spreads to the neocortex, affecting higher cognitive functions. Combined with cholinergic loss from the NBM, cognitive decline accelerates.
Stage 6: End Stage
Alpha-synuclein pathology has spread throughout the entire cortex. All primary sensory and motor areas are affected.
What this actually means
The disease moves through six zones of the brain in order. The first two stages cause gut and sleep problems but no movement trouble. Movement symptoms only appear at stages 3-4. By stages 5-6, thinking and memory are affected.
Picture this: Picture six neighbourhoods along a river. A flood starts upstream (neighbourhood 1) and slowly works downstream. Each neighbourhood gets hit in turn -- and each one brings different problems as it floods.
Why it matters: Knowing the sequence helps doctors connect early symptoms like constipation or vivid dream-acting to what may be coming later. It also shows where future treatments need to intervene -- ideally at stages 1-2, before movement is affected.
The Six Stages - Interactive Timeline
Each stage corresponds to a different region being engulfed by alpha-synuclein pathology. Notice how symptoms at Stages 1–2 are entirely non-motor - they belong to the "hidden disease" that precedes any clinical diagnosis.
Stage 1: The Silent Beginning
Alpha-synuclein pathology appears in the brainstem's lowest levels and the olfactory system. The gut-brain connection via the vagus nerve may be the entry point.
Stage 2: Sleep and Mood
Pathology ascends to the lower pons, affecting noradrenergic and serotonergic centers. Sleep architecture begins to deteriorate.
Stage 3: The Tipping Point
The disease reaches the midbrain. Dopaminergic neurons begin dying in earnest, but compensatory mechanisms mask the damage. The countdown to clinical diagnosis begins.
Stage 4: Diagnosis
Compensation fails. Motor symptoms emerge as dopamine depletion crosses the critical threshold. This is when most patients receive their diagnosis.
Stage 5: Cognitive Decline
Lewy pathology spreads to the neocortex, affecting higher cognitive functions. Combined with cholinergic loss from the NBM, cognitive decline accelerates.
Stage 6: End Stage
Alpha-synuclein pathology has spread throughout the entire cortex. All primary sensory and motor areas are affected.
Body-First vs. Brain-First Subtypes
Braak's framework is powerful, but it does not fit every patient. More recent research - including large autopsy studies and DAT-SPECT imaging - has identified at least two major subtypes based on where the disease appears to originate.
Body-First (Gut/Nose → Brain)
~50% of cases- •Alpha-synuclein originates in the enteric nervous system or olfactory bulb
- •Spreads via the vagus nerve upward into the brainstem
- •Non-motor symptoms (anosmia, constipation, RBD) appear years first
- •Follows the classical Braak caudal-to-rostral pattern
- •Earlier parasympathetic involvement
Brain-First (SNc Onset)
~20–30% of cases- •Pathology appears first in the substantia nigra or limbic cortex
- •Spreads both down into the brainstem and up into the cortex
- •Motor symptoms may appear without the usual non-motor precursors
- •Does NOT follow the classic Braak sequence
- •May be more common in LRRK2 mutation carriers
The body-first vs. brain-first model was formalized by researchers including Per Borghammer. It helps explain why some patients lack the classic prodromal non-motor symptoms and why REM sleep behavior disorder is such a powerful predictor - because it indicates Stage 2 brainstem involvement characteristic of the body-first route.
What this actually means
Not everyone follows the same pattern. In roughly half of cases the disease starts in the gut or nose and climbs into the brain (body-first). In others, it starts directly in the brain and spreads from there (brain-first). This explains why some people get gut symptoms first while others go straight to tremor.
Picture this: Think of two wildfires. One starts at the base of the mountain and burns uphill (body-first). The other starts partway up the slope and burns in both directions (brain-first). Both are the same fire, but they reach different areas at different times.
Why it matters: Recognising which subtype a patient has could help doctors predict their symptom pattern and choose treatments tailored to their particular version of the disease.
Common misconception: Braak's bottom-to-top staging is not wrong -- it accurately describes the majority of cases. But it is not the only route the disease can take.
Body-First vs. Brain-First Subtypes
Braak's framework is powerful, but it does not fit every patient. More recent research - including large autopsy studies and DAT-SPECT imaging - has identified at least two major subtypes based on where the disease appears to originate.
Body-First (Gut/Nose → Brain)
~50% of cases- •Alpha-synuclein originates in the enteric nervous system or olfactory bulb
- •Spreads via the vagus nerve upward into the brainstem
- •Non-motor symptoms (anosmia, constipation, RBD) appear years first
- •Follows the classical Braak caudal-to-rostral pattern
- •Earlier parasympathetic involvement
Brain-First (SNc Onset)
~20–30% of cases- •Pathology appears first in the substantia nigra or limbic cortex
- •Spreads both down into the brainstem and up into the cortex
- •Motor symptoms may appear without the usual non-motor precursors
- •Does NOT follow the classic Braak sequence
- •May be more common in LRRK2 mutation carriers
The body-first vs. brain-first model was formalized by researchers including Per Borghammer. It helps explain why some patients lack the classic prodromal non-motor symptoms and why REM sleep behavior disorder is such a powerful predictor - because it indicates Stage 2 brainstem involvement characteristic of the body-first route.
How Well Does Braak Staging Hold Up?
Braak staging is one of the most influential concepts in Parkinson's research, but it has important caveats. Approximately 70–80% of PD cases at autopsy show a distribution of pathology consistent with the caudal-to-rostral sequence. The remaining 20–30% skip stages, start in the cortex, or do not fit neatly.
Braak staging was derived from post-mortem studies - meaning it reflects the brains of people who died with the disease, not necessarily people who are currently living with it. It cannot be directly assessed in living patients; researchers use biomarkers (DaT-SPECT, skin biopsies, CSF alpha-synuclein) as proxies.
Despite these limitations, the Braak framework remains the foundation for understanding why non-motor symptoms appear first, why early detection efforts focus on the gut and olfactory system, and why treatments that could intervene during the prodromal phase are the holy grail of Parkinson's research.
What this actually means
Braak's 6-stage model fits about 70-80% of cases, which is impressive but not universal. Some patients skip stages or start in different areas. Still, it remains the best map we have for understanding how the disease typically progresses.
Picture this: Think of a weather forecast that is right 75% of the time. You would not ignore it, but you would know it is not perfect. Braak staging is the best forecast available -- reliable for most patients, but not a guarantee for every individual.
Why it matters: Knowing the model's limits is important. It guides research and early detection strategies, but clinicians must stay open to patterns that do not follow the textbook sequence.
How Well Does Braak Staging Hold Up?
Braak staging is one of the most influential concepts in Parkinson's research, but it has important caveats. Approximately 70–80% of PD cases at autopsy show a distribution of pathology consistent with the caudal-to-rostral sequence. The remaining 20–30% skip stages, start in the cortex, or do not fit neatly.
Braak staging was derived from post-mortem studies - meaning it reflects the brains of people who died with the disease, not necessarily people who are currently living with it. It cannot be directly assessed in living patients; researchers use biomarkers (DaT-SPECT, skin biopsies, CSF alpha-synuclein) as proxies.
Despite these limitations, the Braak framework remains the foundation for understanding why non-motor symptoms appear first, why early detection efforts focus on the gut and olfactory system, and why treatments that could intervene during the prodromal phase are the holy grail of Parkinson's research.
The Prodromal Opportunity
The long prodromal phase - estimated at 10–20 yearsbefore motor symptom onset - is both the tragedy and the opportunity in Parkinson's. By the time of diagnosis, enormous damage is already done.
But the prodromal period is also a potential intervention window. If future disease-modifying therapies exist, they will need to be deployed during this phase - before neuronal loss becomes irreversible.
Early detection markers being studied
What this actually means
There is a window of 10-20 years between the disease starting and tremor appearing. During that time, clues like loss of smell, constipation, and vivid dream-acting are visible. Catching the disease in this window -- before most neurons are lost -- is the best hope for future treatments.
Picture this: Imagine a slow leak in a dam. For years the leak is tiny and nobody notices. By the time the dam visibly cracks, most of the structural damage is done. If you could detect the leak early with the right sensors, you could reinforce the dam before it is too late.
Why it matters: Future treatments that slow or stop Parkinson's will need to be given during this early hidden phase to have the greatest impact. Identifying reliable early warning signs is one of the most active areas of research.
The Prodromal Opportunity
The long prodromal phase - estimated at 10–20 yearsbefore motor symptom onset - is both the tragedy and the opportunity in Parkinson's. By the time of diagnosis, enormous damage is already done.
But the prodromal period is also a potential intervention window. If future disease-modifying therapies exist, they will need to be deployed during this phase - before neuronal loss becomes irreversible.
Early detection markers being studied
Key Takeaway
What Scientists Know vs. What's Still Uncertain
Established
- 70–80% of PD cases at autopsy follow the Braak caudal-to-rostral staging sequence.
- The prodromal phase lasts approximately 10–20 years before clinical motor onset.
- Non-motor symptoms - anosmia (>90%), constipation (70–80%), REM sleep disorder (30–50%), and depression (40–50%) - precede motor symptoms.
- Motor symptoms emerge after 50–70% SNc neuron loss and 70–80% striatal dopamine depletion.
- Body-first and brain-first subtypes have been identified with distinct progression patterns.
Still Uncertain
- Does the disease truly start in the gut or nose, or does it start in the brain and spread outward - then inward? The directionality is debated.
- Why do 20–30% of cases not follow Braak staging? Are they genuinely different diseases or just different variants?
- Is alpha-synuclein spreading actually driving progression (the prion hypothesis), or is it just a bystander to a cell-autonomous dying process?
- Can prodromal biomarkers reliably identify the right people for preventive trials before they develop motor symptoms?
Looking ahead: Motor Symptoms
Now that we understand the progression sequence, the next chapter explores what actually happens at the motor level - tremor, rigidity, and bradykinesia - and maps each symptom back to the broken circuits we covered in Brain Anatomy.